Cargando…

Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(−)CD45(+) cells during hepatocellular carcinoma progression

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-associated mortality worldwide in men. Bone marrow-derived cells (BMDCs), including circulating endothelial progenitor cells, have been reported to be involved in the progression of HCC. The complexity of BMDCs inspires further int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xiaolin, Zhou, Hongyuan, Luo, Jingtao, Cui, Yunlong, Li, Huikai, Zhang, Wei, Fang, Feng, Li, Qiang, Zhang, Ti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244973/ https://www.ncbi.nlm.nih.gov/pubmed/28123523 http://dx.doi.org/10.3892/ol.2016.5411

Ejemplares similares

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

Circulating CD133(+)VEGFR2(+) and CD34(+)VEGFR2(+) cells and arterial function in patients with beta-thalassaemia major
por: Cheung, Yiu-fai, et al.
Publicado: (2011)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Blockade of VEGFR2 and Not VEGFR1 Can Limit Diet-Induced Fat Tissue Expansion: Role of Local versus Bone Marrow-Derived Endothelial Cells
por: Tam, Joshua, et al.
Publicado: (2009)

Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus)
por: Yao, Yuchen, et al.
Publicado: (2021)

Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

TBX1 Represses Vegfr2 Gene Expression and Enhances the Cardiac Fate of VEGFR2+ Cells
por: Lania, Gabriella, et al.
Publicado: (2015)

VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis
por: Virtej, Anca, et al.
Publicado: (2016)

Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
por: Xu, Wen Wen, et al.
Publicado: (2014)

Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma
por: Sun, Lin, et al.
Publicado: (2017)

Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
por: Jinnin, Masatoshi, et al.
Publicado: (2008)

VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis
por: D'Haene, Nicky, et al.
Publicado: (2013)

Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex
por: Coon, Brian G., et al.
Publicado: (2015)

Computational Modeling to Quantify the Contributions of VEGFR1, VEGFR2, and Lateral Inhibition in Sprouting Angiogenesis
por: Kühn, Clemens, et al.
Publicado: (2019)

VEGFR2 trafficking: Speed doesn’t kill
por: Zhang, Xi, et al.
Publicado: (2013)

VEGFR2 alteration in Alzheimer’s disease
por: Cho, Sun-Jung, et al.
Publicado: (2017)

Combined clinical features and MRI parameters for the prediction of VEGFR2 in hepatocellular carcinoma patients
por: Zhang, Laizhu, et al.
Publicado: (2022)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
por: Szabo, Emese, et al.
Publicado: (2016)

Comprehensive Analysis of VEGFR2 Expression in HPV-Positive and -Negative OPSCC Reveals Differing VEGFR2 Expression Patterns
por: Uzun, Senem, et al.
Publicado: (2021)

CD144, CD146 and VEGFR-2 properly identify circulating endothelial cell
por: Flores-Nascimento, Mariane Cristina, et al.
Publicado: (2015)

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
por: Bando, H, et al.
Publicado: (2005)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer
por: D’Haene, Nicky, et al.
Publicado: (2018)

VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis
por: Jang, Jeon Yeob, et al.
Publicado: (2017)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

Microtubules Coordinate VEGFR2 Signaling and Sorting
por: Czeisler, Catherine, et al.
Publicado: (2013)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway
por: Ji, Lijun, et al.
Publicado: (2018)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies
por: Meng, Qian, et al.
Publicado: (2016)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis
por: Durré, Tania, et al.
Publicado: (2018)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_212305brbi0cti4gsptg4nkihf